Stockreport

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro [Ya...

Galmed Pharmaceuticals Ltd. - Ordinary Shares  (GLMD) 
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: galmedpharma.investorroom.com
PDF combination treatment, enhancing the effect of Bayer's top selling cancer drug, Stivarga ® (regorafenib); such combination could potentially become a life-cycle IP strat [Read more]